Qsymia's US approval set to fatten revenues at Taiwan's ScinoPharm
This article was originally published in Scrip
The recent US FDA approval of Vivus' anti-obesity drug Qsymia is having knock-on effects half a world away in Asia, where one of the US firm's key active pharmaceutical ingredient (API) suppliers is girding itself to meet expected demand.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.